MedTrace Logo

Study of GRT-R910 COVID-19 Boost Vaccine in Healthy Volunteers

NCT05148962 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2024-12-11

Study results available
· View outcomes & findings →

Summary

The primary objective was to assess the safety and tolerability of 2 different doses (10 or 30 µg) of GRT-R910 when administered as a boost in healthy adults previously vaccinated with the AstraZeneca, Janssen/Johnson and Johnson, Moderna, or Pfizer/BioNTech Coronavirus disease 2019 (COVID-19) vaccines.

Conditions

Interventions

BIOLOGICAL

GRT-R910

Injection administered intramuscularly

Sponsors & Collaborators

  • Gritstone bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Elizabeth Martin, DO · Gritstone bio, Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-09-16
Primary Completion
2023-05-26
Completion
2023-05-26

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05148962 on ClinicalTrials.gov